A team from Germany looked at the rare A.30 variant that was first recorded in Tanzania and later detected in several patients in Angola and Sweden this spring. They compared the mutation to the Beta and Eta variants. Beta was chosen because it has “the highest level” of resistance to antibodies, the researchers said.
According to the study published in the peer-reviewed journal Cellular & Molecular Immunology this week, the A.30 variant showed improved ability to enter most host cells, including kidney, liver, and lung cells.
The mutation “enters certain cell lines with increased efficiency and evades antibody-mediated neutralization,” the study found.
“In summary, A.30 exhibits a cell line preference not observed for other viral variants and efficiently evades neutralization by antibodies elicited by ChAdOx1 nCoV-19 [AstraZeneca] or BNT162b2 [Pfizer] vaccination.”
The variant also proved to be resistant to monoclonal drug Bamlanivimab, which is used for Covid-19 treatment, but was vulnerable to a cocktail of Bamlanivimab and Etesevimab.
A.30 has so far not been listed by the World Health Organization (WHO) as a variant of interest or concern, due to its low prevalence.
(...) RT
